EXTRA-SMALL VESSEL STENTING Resolute Onyx DES

DESIGNED TO DELIVER INEXTRA-SMALL VESSELS

2.0-mm diameter is specifically sized for patients with small vessels:

  • Smallest stent crossing profile1 — less than 1 mm
  • Lowest tip O.D.1
  • 65% of extra-small vessels are located in critical proximal and middle vessel segments2
  • 10-15% of eligible PCIs include extra-small vessels2,3
1

Bench test data on file at Medtronic. Testing performed on Abbott Xience Alpine™*, Abbott Xience Xpedition™*, Biosensors BioMatrix Alpha™*, Biosensors BioMatrix NeoFlex™*, Biotronik Osiro™*, Boston Scientific Promus Premier™*, Boston Scientific Synergy™*, Medtronic Resolute Integrity™, Medtronic Resolute Onyx™, and Terumo Ultimaster™* coronary stents.

2

Schunkert et al. JACC July 1999.

3

Parikh et al. EIJ. 2016.


SUITABLE FOR DIFFICULT-TO-REACH AND TIGHT LESIONS

2.0-mm DES WITH 3.25-mm MSID TO TREAT TAPERED VESSELS

MOST DELIVERABLE STENT1

Most Deliverable Stent
1Bench test data on file at Medtronic. Bench test data may not be indicative of clinical performance. Testing performed on Abbott Xience Alpine™*, Abbott Xience Xpedition™*, Biosensors BioMatrix Alpha™*, Biosensors BioMatrix NeoFlex™*, Biotronik Osiro™*, Boston Scientific Promus Premier™*, Boston Scientific Synergy™*, Medtronic Resolute Integrity™, Medtronic Resolute Onyx™, and Terumo Ultimaster™* coronary stents.

STENT STRUT MALAPPOSITION PERCENTAGE IN FEA MODEL1
(Lower is Better)

Stent strut malapposition percentage in FEA model
1 Data on file at Medtronic. May not be indicative of clinical performance. Testing performed on Resolute Onyx™ DES 3.0 mm x 18 mm, Multi-link 8™* BMS 3.0 mm x 18 mm, Synergy™ DES 3.0 mm x 20 mm.

THINNER STRUTS WITH ENHANCED RADIOPACITY

Core Wire Technology enables thinner struts with enhanced radiopacity

Significant reduction in restenosis is associated with thin struts1,2

  1. Resolute Onyx™ DES 2.0 X 26mm 

Resolute Onyx™ DES incorporates a platinum iridium core with 2.6x density of cobalt shell, for improved radiopacity 

Continuous Sinusoid Technology
1

ISAR STEREO II JACC.2003;41(8:1283–1288. Total patients n = 611 (n = 309 with Multi-link™* BMS, n = 302 with Multi-link™* duet stent)

2

ISAR STEREO I Circulation. June, 2001. Total patients n = 651 (n = 326 with Multi-link™* BMS, n=325 with BX Velocity™* stent) These trials were not powered to show TVR differences.

EXCEPTIONAL CLINICAL OUTCOMES1

0% ST AND LOW TLF RATES AT 12 MONTHS 

RESOLUTE ONYX 2.0 MM CLINICAL STUDY — 1ST MULTICENTER, PROSPECTIVE TRIAL OF 2.0 MM DES

0% ST and Low TLF Rates at 12 months - Exceptional Clinical Outcomes
1

Price et al., JACC Cardiovascular Interventions 2017. N = 101 patients. Study only powered for TLF clinical endpoint.

RESOLUTE POOLED — EXCELLENT RESULTS IN EXTRA-SMALL VESSELS VS. SMALL VESSEL STENTING TARGET LESION REVASCULARISATION (TLR) AT 3 YEARS1

RESOLUTE POOLED—EXCELLENT RESULTS IN EXTRA-SMALL VESSELS VS. SMALL VESSEL STENTING TARGET LESION REVASCULARISATION (TLR) AT 3 YEARS
1

Serra et al, TCT 2014.  Post-hoc RESOLUTE Pooled analysis was not powered for the analysis shown. RESOLUTE FIM, RESOLUTE All Comers, RESOLUTE International, RESOLUTE US, RESOLUTE US 38 mm,  RESOLUTE Japan, RESOLUTE China RCT, RESOLUTE China Registry, Resolute Asia, RESOLUTE Japan SVS